- Home
- FGB vs GUTS Comparison
FGB vs GUTS Comparison
Compare FGB & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- GUTS
- Stock Information
- Founded
- FGB 2007
- GUTS 2010
- Country
- FGB United States
- GUTS United States
- Employees
- FGB N/A
- GUTS N/A
- Industry
- FGB Finance/Investors Services
- GUTS
- Sector
- FGB Finance
- GUTS
- Exchange
- FGB Nasdaq
- GUTS NYSE
- Market Cap
- FGB 58.9M
- GUTS 58.8M
- IPO Year
- FGB N/A
- GUTS 2024
- Fundamental
- Price
- FGB $4.02
- GUTS $1.95
- Analyst Decision
- FGB
- GUTS Buy
- Analyst Count
- FGB 0
- GUTS 1
- Target Price
- FGB N/A
- GUTS $10.00
- AVG Volume (30 Days)
- FGB 53.0K
- GUTS 253.9K
- Earning Date
- FGB 01-01-0001
- GUTS 05-13-2025
- Dividend Yield
- FGB 8.92%
- GUTS N/A
- EPS Growth
- FGB N/A
- GUTS N/A
- EPS
- FGB N/A
- GUTS N/A
- Revenue
- FGB N/A
- GUTS $60,000.00
- Revenue This Year
- FGB N/A
- GUTS N/A
- Revenue Next Year
- FGB N/A
- GUTS N/A
- P/E Ratio
- FGB N/A
- GUTS N/A
- Revenue Growth
- FGB N/A
- GUTS N/A
- 52 Week Low
- FGB $2.85
- GUTS $0.87
- 52 Week High
- FGB $3.74
- GUTS $7.05
- Technical
- Relative Strength Index (RSI)
- FGB 52.90
- GUTS 56.42
- Support Level
- FGB $3.93
- GUTS $1.66
- Resistance Level
- FGB $4.11
- GUTS $1.97
- Average True Range (ATR)
- FGB 0.09
- GUTS 0.17
- MACD
- FGB 0.01
- GUTS -0.00
- Stochastic Oscillator
- FGB 34.29
- GUTS 49.31
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.